Serotype 5 adenoviral vectors with chimeric fibers for gene...

Details Serotype 5 adenoviral vectors with chimeric fibers for gene... Serotype 5 adenoviral vectors with chimeric fibers for gene...

2007-06-26

2007-06-26

Woitach, Joseph (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

C424S093210, C435S325000, C514S04400A

Reexamination Certificate

active

10381857

ABSTRACT:
The invention provides means and methods for transduction of a skeletal muscle cell and/or a muscle cell specific precursor thereof. Provided is the use of a gene delivery vehicle derived from an adenovirus, having a tropism for said cells, for the preparation of a medicament. In a preferred aspect of the invention, said gene delivery vehicle comprises at least a tropism determining part of an adenoviral fiber protein of subgroup B and/or F. More preferably, said gene delivery vehicle comprises at least part of a fiber protein of an adenovirus of stereotype (11, 16, 35, 40 and/or 51) or a functional part, derivative and/or analogue thereof.

REFERENCES:
patent: 4487829 (1984-12-01), Sharp et al.
patent: 4517686 (1985-05-01), Ruoslahti et al.
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4593002 (1986-06-01), Dulbecco
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4797368 (1989-01-01), Carter et al.
patent: 4956281 (1990-09-01), Wallner et al.
patent: 5024939 (1991-06-01), Gorman
patent: 5096815 (1992-03-01), Ladner et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5198346 (1993-03-01), Ladner et al.
patent: 5204445 (1993-04-01), Plow et al.
patent: 5223394 (1993-06-01), Wallner
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5246921 (1993-09-01), Reddy et al.
patent: 5332567 (1994-07-01), Goldenberg
patent: 5349053 (1994-09-01), Landolfi
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5443953 (1995-08-01), Hansen et al.
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5534423 (1996-07-01), Plasson et al.
patent: 5543328 (1996-08-01), Mccelland et al.
patent: 5547932 (1996-08-01), Curiel et al.
patent: 5552311 (1996-09-01), Sorscher et al.
patent: 5559099 (1996-09-01), Wickham et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 5712136 (1998-01-01), Wickham et al.
patent: 5731190 (1998-03-01), Wickham et al.
patent: 5756086 (1998-05-01), Mcclelland et al.
patent: 5770442 (1998-06-01), Wickham et al.
patent: 5837511 (1998-11-01), Flack-Pedersen et al.
patent: 5846782 (1998-12-01), Wickham et al.
patent: 5849561 (1998-12-01), Flack-Pedersen
patent: 5856152 (1999-01-01), Wilson et al.
patent: 5871727 (1999-02-01), Curiel
patent: 5871982 (1999-02-01), Wilson et al.
patent: 5877011 (1999-03-01), Armentano et al.
patent: 5922315 (1999-07-01), Roy
patent: 6033908 (2000-03-01), Bout et al.
patent: 6057155 (2000-05-01), Wickham et al.
patent: 6100086 (2000-08-01), Kaplan et al.
patent: 6127525 (2000-10-01), Crystal et al.
patent: 6287857 (2001-09-01), O'riordan et al.
patent: 6306652 (2001-10-01), Fallaux et al.
patent: 6486133 (2002-11-01), Herlyn et al.
patent: 6492169 (2002-12-01), Vogels et al.
patent: 259212 (1987-08-01), None
patent: 1016726 (1998-12-01), None
patent: 99201545.3 (1999-05-01), None
patent: 1020529 (1999-11-01), None
patent: 0 978 566 (2000-02-01), None
patent: 1 020 529 (2000-07-01), None
patent: 1 067 188 (2001-01-01), None
patent: WO 91/00360 (1991-01-01), None
patent: WO 91/05805 (1991-05-01), None
patent: WO 91/05871 (1991-05-01), None
patent: WO 92/02553 (1992-02-01), None
patent: WO 92/13081 (1992-08-01), None
patent: WO 93/03769 (1993-03-01), None
patent: WO 93/06223 (1993-04-01), None
patent: WO 93/07282 (1993-04-01), None
patent: WO 93/07283 (1993-04-01), None
patent: WO 94/08026 (1994-04-01), None
patent: WO 94/10323 (1994-05-01), None
patent: WO 94/11506 (1994-05-01), None
patent: WO 94/15644 (1994-07-01), None
patent: WO 94/17832 (1994-08-01), None
patent: WO 94/24299 (1994-10-01), None
patent: WO 94/26915 (1994-11-01), None
patent: WO 95/05201 (1995-02-01), None
patent: WO 95/06745 (1995-03-01), None
patent: WO 95/14785 (1995-06-01), None
patent: WO 95/16037 (1995-06-01), None
patent: WO 95/21259 (1995-08-01), None
patent: WO 95/26412 (1995-10-01), None
patent: WO 95/27071 (1995-10-01), None
patent: WO 95/31187 (1995-11-01), None
patent: WO 95/31566 (1995-11-01), None
patent: WO 96/00326 (1996-01-01), None
patent: WO 96/00790 (1996-01-01), None
patent: WO 96/07739 (1996-03-01), None
patent: WO 96/10087 (1996-04-01), None
patent: WO 96/12030 (1996-04-01), None
patent: WO 96/13597 (1996-05-01), None
patent: WO 96/13598 (1996-05-01), None
patent: WO 96/14837 (1996-05-01), None
patent: WO 96/17073 (1996-06-01), None
patent: WO 96/ 18740 (1996-06-01), None
patent: WO 96/24453 (1996-08-01), None
patent: WO 96/26281 (1996-08-01), None
patent: WO 96/35798 (1996-11-01), None
patent: WO 97/00326 (1997-01-01), None
patent: WO 97/12986 (1997-04-01), None
patent: WO 97/20575 (1997-06-01), None
patent: WO 97/38723 (1997-10-01), None
patent: WO 98/07865 (1998-02-01), None
patent: WO 98/11221 (1998-03-01), None
patent: WO 98/13499 (1998-04-01), None
patent: WO 98/22609 (1998-05-01), None
patent: WO 98/ 32842 (1998-07-01), None
patent: WO 98/40509 (1998-09-01), None
patent: WO 98/49300 (1998-11-01), None
patent: WO 98/50053 (1998-11-01), None
patent: WO 99/32647 (1999-07-01), None
patent: WO 99/47180 (1999-09-01), None
patent: WO 99/55132 (1999-11-01), None
patent: WO 99/58646 (1999-11-01), None
patent: WO 00/03029 (2000-01-01), None
patent: WO 00/24730 (2000-05-01), None
patent: WO 00/31285 (2000-06-01), None
patent: WO 00/52186 (2000-09-01), None
patent: WO 00/70071 (2000-11-01), None
patent: WO 01/04334 (2001-01-01), None
patent: WO 01/90158 (2001-11-01), None
patent: WO 02/24730 (2002-03-01), None
patent: WO 02/27006 (2002-04-01), None
Deonarain (1998) Expert Opin. Ther. Pat., 8: 53-69.
Khurana, et al. (2001) Hypertension, 38: 1210-16.
Schiavone, et al. (2004) Curr. Pharm. Des., 10: 769-84.
Bouri, et al. (1999) Hum. Gene Therapy, 10(12): 1633-40.
Kypson, et al. (1999) Gene Therapy, 6: 1298-1304.
Tsukamoto, et al. (1999) Gene Therapy, 6: 1331-35.
Moisset, et al. (1998) Gene Therapy, 5: 1340-46.
Abrahamsen et al., “Construction of an Adenovirus Type 7a EIA Vector,” Journal of Virology, Nov. 1997, p. 8946-8951 vol. 71, No. 11.
Albiges-Rizo et al., “Human Adenovirus Serotype 3 Fiber Protein,” Journal of Biological Chemistry, 266(6), 3961-3967 (1991).
Anderson, Nature, “Human gene therapy,” Apr. 1998, vol. 392, pp. 25-30.
Athappilly et al., “The Refined Crystal Structure of Hexon, the Major Coat Protein of Adenovirus Type 2, at 2•9 A Resolution,” J. Mol. Biol. (1994) 242, 430-455.
Bai et al., “Mutations That Alter an Arg-Gly-Asp (RGD) Sequence in the Adenovirus Type 2 Penton Base Protein Abolish Its Cell-Rounding Activity and Delay Virus Reproduction in Flat Cells,” Journal of Virology, 67(9), 5198-5205 (1993).
Bailey et al., “Phylogenetic Relationships among Adenovirus Serotypes,” Virology, 205, 439-452 (1994).
Ball-Goodrich et al., “Parvoviral Target Cell Specificity: Acquisition of Fibrotropism by a Mutant of the Lymphotropic Strain of Minute Virus of Mice Involves Multiple Amino Acid Substitutions within the Capsid,” Virology, 184, 175-186 (1991).
Basler et al., Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35, 1996, Gene 170:249-254.
Basler et al., “Subgroup B Adenovirus Type 35 Early Region 3 mRNAs Differ from Those of the Subgroup C Adenoviruses,” VIROLOGY, 215, 165-177 (1996).
Batra et al., “Receptor-mediated gene delivery employing lectin-binding specificity,” Gene Therapy, 1, 255-260 (1994).
Berendsen, Herman J.C., A Glimpse of the Holy Grail, Science, 1998, vol. 282, pp. 642-643.
Boursnell et al., “In vitro construction of a recombinant adenovirus Ad2:Ad5,” Gene, 13, 311-317 (1981).
Bridge et al., “Adenovirus Early Region 4 and Viral DNA Synthesis,” Virology 193, 794-801 (1993).
Brody et al., “Adenovirus-Mediated in Vivo Gene Transfer,” Annals New York Academy of Sciences pp. 90-100.
Caillet-Boudin et al., “Functional and Structural Effects of an Ala to Val Mutation in

Affiliated with

Also associated with

Rating

Serotype 5 adenoviral vectors with chimeric fibers for gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Serotype 5 adenoviral vectors with chimeric fibers for gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serotype 5 adenoviral vectors with chimeric fibers for gene... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3830227